Lesson plan

Cianergoline

Cianergoline ( ), also known as 355/1057 or as 2-cyano-3-(6-methylergolin-8β-yl)propionamide (2-CMEBP), is a dopamine receptor agonist described as an antihypertensive agent of the ergoline family which was never marketed. It has atypical properties as a dopamine receptor agonist compared to other ergolines, for instance having less central activity and showing predominant cardiovascular effects. In addition to its dopamine receptor agonism, cianergoline may interact with α-adrenergic receptors, which may or may not also be involved in its antihypertensive effects. The drug was first described in the scientific literature by 1983. It was studied for treatment of essential hypertension.

Back to article

Article summary

Cianergoline ( ), also known as 355/1057 or as 2-cyano-3-(6-methylergolin-8β-yl)propionamide (2-CMEBP), is a dopamine receptor agonist described as an antihypertensive agent of the ergoline family which was never marketed. It has atypical properties as a dopamine receptor agonist compared to other ergolines, for instance having less central activity and showing predominant cardiovascular effects. In addition to its dopamine receptor agonism, cianergoline may interact with α-adrenergic receptors, which may or may not also be involved in its antihypertensive effects. The drug was first described in the scientific literature by 1983. It was studied for treatment of essential hypertension.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.